Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B/F/TAF in Neonates Exposed to HIV-1
NCT07055451Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-emergent Adverse Events at 8 weeks, Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities at 8 weeks and 1 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07055451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055451.